Evidence map›Paper›PMID 32189449›Full record

ArticleEMBO reports2020

Controlling Smad4 signaling with a Wip.

Peter Ten Dijke, David Baker

Open access · hybridAbstract readNewsComment
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Peter Ten DijkeDepartment Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-7234-342X
David BakerDepartment Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
Leiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Members of the transforming growth factor-β (TGF-β) family play key roles in embryogenesis and in maintaining tissue homeostasis, and their perturbation can result in a broad range of diseases. One way TGF-β family signaling pathways are kept in check is by reversible (de)phosphorylation of intracellular Smad effectors. In this issue of EMBO Reports, Park et al [1] identify the phosphatase wild-type p53-induced phosphatase 1 (Wip1) as a negative regulator of TGF-β family signaling. Mechanistically, Wip1 constrains TGF-β family signaling through direct dephosphorylation of Thr277, an activating MAP kinase phosphorylation site located in the linker region of the common mediator Smad4.

Indexed as

Signal TransductionTransforming Growth Factor betaMitogen-Activated Protein KinasesPhosphorylationReceptors, Transforming Growth Factor betaMitogen-Activated Protein KinasesReceptors, Transforming Growth Factor betaTransforming Growth Factor beta

Identifiers

PMID32189449
PMCPMC7202217
OpenAlexW3012385075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.